- Home
- CANF vs MET Comparison
CANF vs MET Comparison
Compare CANF & MET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MET
- Stock Information
- Founded
- CANF 1994
- MET 1863
- Country
- CANF Israel
- MET United States
- Employees
- CANF N/A
- MET N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MET Life Insurance
- Sector
- CANF Health Care
- MET Finance
- Exchange
- CANF Nasdaq
- MET Nasdaq
- Market Cap
- CANF 7.9M
- MET N/A
- IPO Year
- CANF N/A
- MET N/A
- Fundamental
- Price
- CANF $1.12
- MET $77.59
- Analyst Decision
- CANF Strong Buy
- MET Strong Buy
- Analyst Count
- CANF 2
- MET 13
- Target Price
- CANF $14.00
- MET $92.69
- AVG Volume (30 Days)
- CANF 444.9K
- MET 3.3M
- Earning Date
- CANF 05-20-2025
- MET 04-30-2025
- Dividend Yield
- CANF N/A
- MET 2.93%
- EPS Growth
- CANF N/A
- MET 112.38
- EPS
- CANF N/A
- MET 6.14
- Revenue
- CANF $674,000.00
- MET $73,494,000,000.00
- Revenue This Year
- CANF $461.72
- MET $7.37
- Revenue Next Year
- CANF N/A
- MET $3.92
- P/E Ratio
- CANF N/A
- MET $12.64
- Revenue Growth
- CANF N/A
- MET 8.77
- 52 Week Low
- CANF $1.02
- MET $65.21
- 52 Week High
- CANF $4.69
- MET $89.05
- Technical
- Relative Strength Index (RSI)
- CANF 40.25
- MET 54.25
- Support Level
- CANF $1.02
- MET $75.92
- Resistance Level
- CANF $1.20
- MET $78.16
- Average True Range (ATR)
- CANF 0.06
- MET 1.91
- MACD
- CANF 0.01
- MET 0.63
- Stochastic Oscillator
- CANF 41.30
- MET 85.65
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).